Bio Preventive Medicine Corp.
Bio Preventive Medicine Corp., a clinical-staged biotech company, focusing on early detection and prevention of diseases. The company offers solutions in prevention, screening, and monitoring chronic diseases and cancers management. It also provides DNlite test, a series of patented and clinically validated non-invasive urine test for monitoring the progression of diabetic nephropathy, including … Read more
Bio Preventive Medicine Corp. (6810) - Net Assets
Latest net assets as of June 2025: NT$358.00 Million TWD
Based on the latest financial reports, Bio Preventive Medicine Corp. (6810) has net assets worth NT$358.00 Million TWD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$473.47 Million) and total liabilities (NT$115.46 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$358.00 Million |
| % of Total Assets | 75.61% |
| Annual Growth Rate | 19.18% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 88.03 |
Bio Preventive Medicine Corp. - Net Assets Trend (2020–2024)
This chart illustrates how Bio Preventive Medicine Corp.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Bio Preventive Medicine Corp. (2020–2024)
The table below shows the annual net assets of Bio Preventive Medicine Corp. from 2020 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$407.09 Million | +190.93% |
| 2023-12-31 | NT$139.93 Million | -0.43% |
| 2022-12-31 | NT$140.54 Million | +1.89% |
| 2021-12-31 | NT$137.94 Million | -31.64% |
| 2020-12-31 | NT$201.77 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Bio Preventive Medicine Corp.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 29901100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | NT$494.49 Million | 121.47% |
| Other Components | NT$437.84 Million | 107.55% |
| Total Equity | NT$407.09 Million | 100.00% |
Bio Preventive Medicine Corp. Competitors by Market Cap
The table below lists competitors of Bio Preventive Medicine Corp. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ORION ENRGY SYS
BE:5A4
|
$4.96K |
|
CHINA COMM SRVCS-H
MU:CMW
|
$4.96K |
|
Perk International Inc
PINK:PRKI
|
$4.97K |
|
KASATI
VN:KST
|
$4.97K |
|
ICDS Limited
NSE:ICDSLTD
|
$4.96K |
|
National Development Bank PLC
CM:NDBN0000
|
$4.96K |
|
Pakistan Cables Ltd
KAR:PCAL
|
$4.95K |
|
Bera Holding AS
IS:BERA
|
$4.95K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Bio Preventive Medicine Corp.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 139,928,000 to 407,090,000, a change of 267,162,000 (190.9%).
- Net loss of 87,559,000 reduced equity.
- New share issuances of 345,000,000 increased equity.
- Other factors increased equity by 9,721,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-87.56 Million | -21.51% |
| Share Issuances | NT$345.00 Million | +84.75% |
| Other Changes | NT$9.72 Million | +2.39% |
| Total Change | NT$- | 190.93% |
Book Value vs Market Value Analysis
This analysis compares Bio Preventive Medicine Corp.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.55x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 2.61x to 1.55x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | NT$6.82 | NT$17.80 | x |
| 2021-12-31 | NT$4.47 | NT$17.80 | x |
| 2022-12-31 | NT$4.43 | NT$17.80 | x |
| 2023-12-31 | NT$4.12 | NT$17.80 | x |
| 2024-12-31 | NT$11.46 | NT$17.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Bio Preventive Medicine Corp. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -21.51%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -712.04%
- • Asset Turnover: 0.02x
- • Equity Multiplier: 1.30x
- Recent ROE (-21.51%) is above the historical average (-41.05%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | -32.13% | 0.00% | 0.00x | 1.10x | NT$-85.01 Million |
| 2021 | -48.74% | -7709.52% | 0.01x | 1.11x | NT$-81.02 Million |
| 2022 | -50.48% | -3258.61% | 0.01x | 1.94x | NT$-84.99 Million |
| 2023 | -52.37% | -6066.64% | 0.00x | 1.89x | NT$-87.28 Million |
| 2024 | -21.51% | -712.04% | 0.02x | 1.30x | NT$-128.27 Million |
Industry Comparison
This section compares Bio Preventive Medicine Corp.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,057,086,200
- Average return on equity (ROE) among peers: 8.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Bio Preventive Medicine Corp. (6810) | NT$358.00 Million | -32.13% | 0.32x | $4.96K |
| Synbio Tech Inc. (1295) | $863.17 Million | 18.53% | 0.78x | $21.14K |
| Apex Biotechnology Corp (1733) | $1.92 Billion | 19.33% | 0.42x | $65.42 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $1.77 Billion | 2.60% | 1.02x | $129.70 Million |
| Panion & BF Biotech Inc (1760) | $835.25 Million | 10.84% | 0.49x | $122.27 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $1.62 Billion | 0.90% | 0.98x | $40.94 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $1.10 Billion | 14.01% | 0.66x | $45.00 Million |
| Level Biotechnology (3118) | $542.40 Million | 10.78% | 0.50x | $22.42 Million |
| GenMont Biotech Inc (3164) | $737.87 Million | 20.00% | 0.85x | $30.93 Million |
| Medigen Biotechnology (3176) | $650.39 Million | 0.00% | 0.08x | $90.59 Million |
| Sagittarius Life Science (3205) | $531.71 Million | -16.25% | 0.27x | $56.62 Million |